Assessment of Efficacy of Vardenafil in Subjects With Erectile Dysfunction and Diabetes, Hypertension or Hyperlipidemia
NCT ID: NCT00668109
Last Updated: 2014-12-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
614 participants
INTERVENTIONAL
2003-12-31
2004-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
Levitra (Vardenafil, BAY38-9456)
10 mg one hour prior to sexual intercourse
Arm 2
Tadalafil
10 mg taken approximately 24 hours prior to sexual intercourse
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Levitra (Vardenafil, BAY38-9456)
10 mg one hour prior to sexual intercourse
Tadalafil
10 mg taken approximately 24 hours prior to sexual intercourse
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bruxelles - Brussel, , Belgium
Bruxelles - Brussel, , Belgium
Edegem, , Belgium
Roeselare, , Belgium
Barranquilla, , Colombia
Bogotá, , Colombia
Medellín, , Colombia
Santa Fé de Bogotá, , Colombia
Helsinki, , Finland
Helsinki, , Finland
Oulu, , Finland
Freiburg im Breisgau, Baden-Wurttemberg, Germany
Stuttgart, Baden-Wurttemberg, Germany
Königsbrunn, Bavaria, Germany
München, Bavaria, Germany
München, Bavaria, Germany
Weiden, Bavaria, Germany
Hamburg, City state of Hamburg, Germany
Marburg, Hesse, Germany
Hanover, Lower Saxony, Germany
Osnabrück, Lower Saxony, Germany
Westerstede, Lower Saxony, Germany
Mönchengladbach, North Rhine-Westphalia, Germany
Berlin, State of Berlin, Germany
Berlin, State of Berlin, Germany
Berlin, State of Berlin, Germany
Haifa, Israel, Israel
Jerusalem, Israel, Israel
Tel Aviv, Israel, Israel
Tel Litwinsky, , Israel
Catania, , Italy
Milan, , Italy
Milan, , Italy
Milan, , Italy
Padua, , Italy
Pavia, , Italy
Perugia, , Italy
Pisa, , Italy
Durango, Durango, Mexico
Iguala de la Independencia, Guerrero, Mexico
México, D. F., México, D. F., Mexico
Monterrey, Nuevo León, Mexico
México, D.F., , Mexico
México, D.F., , Mexico
Nijverdal, , Netherlands
Utrecht, , Netherlands
Moelv, , Norway
Oslo, , Norway
Sarpsborg, , Norway
Trondheim, , Norway
Callao, , Peru
Lima, , Peru
Lima, , Peru
George, Eastern Cape, South Africa
Johannesburg, Gauteng, South Africa
Pretoria, Gauteng, South Africa
Durban, KwaZulu-Natal, South Africa
Durban, KwaZulu-Natal, South Africa
Durban, KwaZulu-Natal, South Africa
Newcastle, KwaZulu-Natal, South Africa
Pietermaritzburg, KwaZulu-Natal, South Africa
Cape Town, Western Cape, South Africa
Cape Town, Western Cape, South Africa
A Coruña, A Coruña, Spain
Sant Joan d'Alacant, Alicante, Spain
L'Hospitalet de Llobregat, Barcelona, Spain
Castellon, Castellón de La Plana, Spain
Málaga, Málaga, Spain
Palma de Mallorca, Palma de Mallorca, Spain
Vigo, Pontevedra, Spain
Zaragoza, Zaragoza, Spain
Borås, , Sweden
Skövde, , Sweden
Stockholm, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10893
Identifier Type: -
Identifier Source: org_study_id